Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time
Authors:
Open Access
- 1 March 2020
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 18 (3) , 278-285
Abstract
Background: Restricted mean survival time (RMST) overcomes limitations of current measures of survival benefits because it directly captures information of the entire area under Kaplan-Meier survival curves. Using RMST difference (absolute survival benefit) and RMST ratio (relative survival benefit), we quantified the magnitude of survival benefits of recent oncology drugs and compared immunotherapies with nonimmunotherapies. Methods: Kaplan-Meier curves were extracted from phase II/III randomized controlled trials used by the FDA for oncology drug approvals from January 2011 through November 2017 with overall survival (OS) or progression-free survival (PFS) as primary endpoints. RMST differences, ratios, and their 95% confidence intervals were meta-analyzed to estimate absolute and relative survival benefits of contemporary oncology drugs and to compare immunotherapies with nonimmunotherapies. Meta-regression was conducted to adjust for potential confounders. Results: Ninety-four trials with a total of 51,639 patients were included. Overall absolute survival benefits (RMST differences) were 1.55 months for OS (95% CI, 1.32–1.77) and 2.99 months for PFS (95% CI, 2.65–3.33). Overall relative survival benefits (RMST ratios) were 1.11 for OS (95% CI, 1.09–1.13) and 1.42 for PFS (95% CI, 1.36–1.48). Immunotherapy absolute PFS benefit was less than that of nonimmunotherapy (1.56 vs 3.23 months), whereas immunotherapy absolute OS benefit was larger than that of nonimmunotherapy by 0.59 months (2.02 vs 1.43 months). Adjusted OS RMST difference was 0.91 months greater for immunotherapy than for nonimmunotherapy after adjusting for confounders. Conclusions: Absolute survival benefits of recent oncology drugs are modest. Survival benefits of immunotherapies are not dramatically superior to those of nonimmunotherapies. Routine reporting and use of RMST may help patients, physicians, and payers make more informed and responsible decisions regarding the care of patients with cancer.Keywords
This publication has 43 references indexed in Scilit:
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisJournal of Clinical Oncology, 2014
- New modalities of cancer treatment for NSCLC: focus on immunotherapyCancer Management and Research, 2014
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Medical Research Methodology, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based RegimenJournal of Clinical Oncology, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986